Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Figure 3

Tumor response to ¹⁸⁸Re-6D2 mAb in patients. (a) ¹⁸FDG PET/CT of a patient from Phase Ia: left panel—10 days before the study showing coronal and transaxial views, right panel—7 days after the dose of ¹⁸⁸Re-6D2 mAb; (b) patient from Phase Ib with a stable disease who received 30 mCi/16 mg ¹⁸⁸Re-6D2 mAb: left panel—¹⁸FDG PET/CT 10 days before the study; right panel—¹⁸FDG PET/CT 24 weeks after the study; (c) patient from Phase Ib with progressive disease who received 54 mCi/47 mg ¹⁸⁸Re-6D2 mAb: panels from left to right—CT 6 months prior to study; 1 month prior to study; at the time of ¹⁸⁸Re-6D2 mAb administration; 1 month after administration.

(a)

(b)

(c)